Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001

Joshua Brumm, Chief Executive Officer of Crescent Biopharma

“Our team’s outstanding execution has enabled us to rapidly advance three programs into the clinic in 2026 and make significant progress in developing next-generation IO, ADC and combination therapies. Together with our partner, Kelun-Biotech, we have achieved seven IND clearances to date, and by mid-2027, we expect more than 2,000 patients to have been dosed across our portfolio. We remain focused on generating meaningful clinical data and expect to begin sharing results in the first quarter of 2027, including data from ASCEND, which is enrolling first-line NSCLC patients globally, including in the United States and Europe. We believe these data can support the initiation of the first of multiple Phase 3 studies of CR-001 in early 2028”

Joshua Brumm, Chief Executive Officer of Crescent Biopharma

“Our partnership with Kelun-Biotech brings together two companies with a shared commitment to accelerating the development of potentially transformative therapies for people living with cancer. Multiple combination trials of CR-001 and sac-TMT are already underway in China, with additional ADC combination studies planned. In 2026, we established the foundation for the next phase of Crescent’s growth: delivering multiple important clinical readouts across our IO and ADC portfolio, beginning early next year”